A study testing whether a new weekly shot, tirzepatide, can help people with atrial fibrillation lose weight.

Recruiting now. Registry record last updated January 13, 2026.

Who can join: Adults 18 to 80, have atrial fibrillation, BMI 27+.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.2 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor The Cleveland ClinicDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 100

What this study is for

Primary condition: Atrial Fibrillation. Also studied in: Obesity.

Full scientific study title: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation.

Who can join

Age18 to 80SexAnyBMI27 to 60

Adults 18 to 80, have atrial fibrillation, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Sinus rhythm at randomization
Sustained normal sinus rhythm (or)
Normal sinus rhythm at office visit
Age ≥18 to ≤80 years old
BMI ≥ 27 and ≤60 kg/m2

Key exclusion criteria

AFIB ablation within the last 6 months
Planned ablation prior to 3 months post randomization
Significant cardiac valvular disease with planned cardiac valve intervention/surgery in the next 12 months
Severe uncompensated cardiopulmonary disease
New York Heart Association Class III or IV

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Ohio1 site

Cleveland Clinic
Cleveland, Ohio
Jeannine Ramsey, RN, BSN216-445-4063RAMSEYJ8@ccf.org

Follow this trial

We email you if NCT06802081 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: April 8, 2025. Expected completion: June 1, 2027. Last updated on ClinicalTrials.gov: January 13, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.